氟西汀在构巢曲霉中的重组活性。

Recombinogenic activity of fluoxetine in Aspergillus nidulans.

机构信息

Departamento de Biologia Celular e Genética, Universidade Estadual de Maringá, Maringá, PR Brazil.

出版信息

Drug Chem Toxicol. 2009;32(4):338-43. doi: 10.1080/01480540903155085.

PMID:19793026

Abstract

The recombinogenic potential of fluoxetine, an antidepressant widely prescribed in the treatment of depressive disorders in cancer patients, was investigated in this study. A heterozygous diploid strain of Aspergillus nidulans was utilized. Fluoxetine at 7.5, 15, and 30 microM concentrations induced homozygosity of several nutritional genetic markers and significantly increased their homozygotization index values. Since mitotic recombination is a mechanism leading to malignant growth through the loss of a functional copy of a heterozygous tumor-suppressor gene, fluoxetine may be characterized as an inducer of secondary malignancies in cancer patients after antidepressant treatment.

摘要

本研究调查了氟西汀（一种广泛用于治疗癌症患者抑郁障碍的抗抑郁药）的重组潜能。使用了一种异核二倍体的构巢曲霉。氟西汀在 7.5、15 和 30 μM 浓度下诱导了几个营养遗传标记的纯合性，并显著增加了它们的纯合化指数值。由于有丝分裂重组是通过丧失杂合肿瘤抑制基因的一个功能拷贝而导致恶性生长的机制，因此氟西汀可能被描述为癌症患者在抗抑郁治疗后发生继发性恶性肿瘤的诱导剂。